Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–75
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
All Participants:
Must have a body mass index (BMI) between 18 and 40 kg/m\^2 (inclusive), and body weight ≥ 50 kg.
Mild, Moderate, or Severe Hepatic Impairment Participants:
Mild, moderate, or severe hepatic impairment (HI) or cirrhosis due to chronic hepatic disease and/or prior alcohol use.
Mild, moderate, and severe HI participants will be enrolled according to the Child-Pugh classification score.
Matched Healthy Participants:
Free of any clinically significant disease that would interfere with the study evaluations.
Normal hepatic function participants will be enrolled and matched individually with HI participants with respect to age (± 10 years), weight (± 20%), sex, and race/ethnicity (Japanese and Chinese participants vs non-Japanese and non-Chinese participants).
You may not be if
All Participants:
History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to screening that exceeds 7 units for women, or 14 units for men of alcohol per week (1 unit = 340 mL of beer 5%, 140 mL of wine 12%, or 45 mL of distilled alcohol 40%).
Must not have had any prior exposure to BMS-986278.
Mild, Moderate, or Severe Hepatic Impairment Participants:
Acute liver disease (eg, caused by an acute infection or drug toxicity).
History of initial stage/planned liver transplantation within 6 months of screening or has received a liver transplant.
Matched Healthy Participants:
Any significant medical condition, or psychiatric illness that would prevent participant from participating in the study.
Clareo Health | Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment
